Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for methylprednisolone
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on methylprednisolone or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on methylprednisolone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. OBJECTIVE: To compare the effects of methotrexate (MTX), alone or in combination with intravenous (IV) methylprednisolone (MP) or infliximab, on magnetic resonance imaging (MRI)-detected synovitis, bone edema, and erosive changes in patients
Intravenous injection of methylprednisolone reduces the incidence of postextubation stridor in intensive care unit patients PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?
12-h pretreatment with methylprednisolone versus placebo for prevention of postextubation laryngeal oedema: a randomised double-blind trial. The efficacy of corticosteroids in reducing the incidence of postextubation laryngeal oedema is controversial. We aimed to test our hypothesis that methylprednisolone started 12 h before a planned extubation could prevent postextubation laryngeal oedema.We did a placebo-controlled, double-blind multicentre trial in 761 adults in intensive-care units (...) . Patients who were ventilated for more than 36 h and underwent a planned extubation received intravenous 20 mg methylprednisolone (n=380) or placebo (381) 12 h before extubation and every 4 h until tube removal. The primary endpoint was occurrence of laryngeal oedema within 24 h of extubation. Laryngeal oedema was clinically diagnosed and deemed serious if tracheal reintubation was needed. Analyses were done on a per protocol and intention-to-treat basis. This trial is registered at ClinicalTrials.gov
2007LancetControlled trial quality: predicted high
Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Neuropsychiatric involvement in systemic lupus erythematosus is complex and several clinical presentations are related to this disease such as: convulsions, chronic headache, transverse myelitis, vascular brain disease, psychosis and neural cognitive dysfunction. This systematic review is an update of a review performed in 2000.To assess the efficacy and safety (...) of cyclophosphamide and methylprednisolone in the treatment of neuropsychiatric manifestations of systemic lupus erythematosus.We searched EMBASE, LILACS, Cochrane Central Register of Controlled Trials (CENTRAL) and MEDLINE up to and including May 2005. Additional articles were sought through handsearching in relevant journals. There were no language restrictions.All randomised controlled trials that compared cyclophosphamide to methylprednisolone were included. Patients of any age and gender were included
Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. Vestibular neuritis is the second most common cause of peripheral vestibular vertigo. Its assumed cause is a reactivation of herpes simplex virus type 1 infection. Therefore, corticosteroids, antiviral agents, or a combination of the two might improve the outcome in patients with vestibular neuritis.We performed a prospective, randomized, double-blind, two-by-two factorial trial in which patients with acute vestibular (...) neuritis were randomly assigned to treatment with placebo, methylprednisolone, valacyclovir, or methylprednisolone plus valacyclovir. Vestibular function was determined by caloric irrigation, with the use of the vestibular paresis formula (to measure the extent of unilateral caloric paresis) within 3 days after the onset of symptoms and 12 months afterward.Of a total of 141 patients who underwent randomization, 38 received placebo, 35 methylprednisolone, 33 valacyclovir, and 35 methylprednisolone plus
Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Treatment of adults with autoimmune thrombocytopenic purpura (AITP) is based more on individual experience than on results of controlled studies. We compared intravenous immunoglobulin with high-dose methylprednisolone in untreated adults with severe AITP and assessed efficacy of subsequent oral (...) steroids compared with placebo. Primary outcome was number of days with platelet count greater than 50 x 10(9)/L within the first 21 days.We did a randomised multicentre trial based on a 232 design. 122 adults with severe AITP (platelet count < or =20 x 10(9)/L) were randomly assigned to receive either intravenous immunoglobulin or high-dose methylprednisolone on days 1-3 (randomisation A), and then to receive either oral prednisone or placebo (randomisation B) on days 4-21. Analysis was by intention
2002LancetControlled trial quality: predicted high
Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus. Neuropsychiatric involvement in systemic lupus erythematosus is complex and several clinical presentations are related to this disease such as: convulsions, chronic headache, transverse myelitis, vascular brain disease, psychosis and neural cognitive dysfunction.To assess the efficacy and safety of cyclophosphamide and methylprednisolone in the treatment (...) of neuropsychiatric manifestations of systemic lupus erythematosus on mortality and side effects.We searched EMBASE, LILACS, Cochrane Controlled Trials Register and MEDLINE up to and including December 1999, additional articles were sought through handsearching in relevant journals, using the search strategy described in the Cochrane Handbook [Dickersin 1994]. There were no language restrictions.All randomized controlled trials which compared cyclophosphamide to methylprednisolone were to be included. Patients
Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review Sauerland S, Nagelschmidt M, Mallmann P, Neugebauer E A Authors' objectives To conduct a risk-benefit analysis using a meta-analysis, for the comparison of complication rates (...) and clinical advantages associated with the use of high-dose methylprednisolone in surgical patients. Searching PubMed and the Cochrane Library (Issue 2, 2000) were searched using the term 'methylprednisolone' and the publication type 'randomised controlled trial'. Both searches were repeated in August 2000. The references of all articles and two related Cochrane reviews were checked for further studies. The manufacturer of a commonly-used MPSS was also contacted for further information. Study selection
A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations Miller D M, Weinstock-Guttman B, Bethoux F, Lee J C, Beck G, Block V, Durelli L, LaMantia L, Barnes D, Sellebjerg F, Rudick R A Authors' objectives To assess methylprednisolone (MP) at different doses, and in comparison with other (...) steroid products, in the treatment of multiple sclerosis exacerbations. Searching MEDLINE was searched from 1981 to 1998, and EMBASE from 1980 to 1998, combining 'Multiple Sclerosis' (as an index term) with 'Methylprednisolone' (either as an index term or in 'authors, title or abstract'). The references of identified articles and recent review articles were also examined. No restrictions on publication language were specified. Study selection Study designs of evaluations included in the review
High dose methylprednisolone in the management of acute spinal cord injury: a systematic review from a clinical perspective High dose methylprednisolone in the management of acute spinal cord injury: a systematic review from a clinical perspective High dose methylprednisolone in the management of acute spinal cord injury: a systematic review from a clinical perspective Short D J, El Masry W S, Jones P W Authors' objectives To evaluate the evidence for an effect of high-dose methylprednisolone (...) (MPSS) on neurological improvement, following acute spinal cord injury (ASCI). Searching MEDLINE was searched from 1966 through December 1999 using the terms 'spinal cord injury' and 'methylprednisolone', or 'spinal cord injury' and 'dexamethasone', with no other restrictions. Additional relevant studies were located by examining the references of a review for pharmacological treatment of ASCI on the Cochrane Database of Systematic Reviews, and by manually checking the reference lists
Intrathecal methylprednisolone for intractable postherpetic neuralgia. There is no effective treatment for intractable postherpetic neuralgia. Because there is evidence that postherpetic neuralgia has an inflammatory component, we assessed treatment with intrathecally administered methylprednisolone to reduce pain in patients with this disorder.We enrolled 277 patients who had had intractable postherpetic neuralgia for at least one year, 270 of whom were followed for two years. The patients (...) were randomly assigned to receive intrathecal methylprednisolone and lidocaine (3 ml of 3 percent lidocaine with 60 mg of methylprednisolone acetate, 89 patients), lidocaine alone (3 ml of 3 percent lidocaine, 91 patients), or no treatment (90 patients) once per week for up to four weeks. Each weekly dose was injected into the lumbar intrathecal space. Pain was evaluated before randomization, at the end of the treatment period, and then four weeks, one year, and two years later. Samples
Injection with methylprednisolone proximal to the carpal tunnel: randomised double blind trial. To assess the effect of a 40 mg methylprednisolone injection proximal to the carpal tunnel in patients with the carpal tunnel syndrome.Randomised double blind placebo controlled trial.Outpatient neurology clinic in a district general hospital.Patients with symptoms of the carpal tunnel syndrome for more than 3 months, confirmed by electrophysiological tests and aged over 18 years.Injection with 10 mg (...) lignocaine (lidocaine) or 10 mg lignocaine and 40 mg methylprednisolone. Non-responders who had received lignocaine received 40 mg methylprednisolone and 10 mg lignocaine and were followed in an open study.Participants were scored as having improved or not improved. Improved was defined as no symptoms or minor symptoms requiring no further treatment.At 1 month 6 (20%) of 30 patients in the control group had improved compared with 23 (77%) of 30 patients the intervention group (difference 57% (95
Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?
Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. No pharmacological therapeutic protocol has been found effective in modifying the clinical course of acute respiratory distress syndrome (ARDS) and mortality remains greater than 50%.To determine the effects of prolonged methylprednisolone therapy on lung function and mortality in patients with unresolving ARDS.Randomized, double-blind, placebo-controlled (...) trial.Medical intensive care units of 4 medical centers.Twenty-four patients with severe ARDS who had failed to improve lung injury score (LIS) by the seventh day of respiratory failure.Sixteen patients received methylprednisolone and 8 received placebo. Methylprednisolone dose was initially 2 mg/kg per day and the duration of treatment was 32 days. Four patients whose LIS failed to improve by at least 1 point after 10 days of treatment were blindly crossed over to the alternative treatment.Primary outcome
Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. An intravenous rather than oral course of methylprednisolone is often prescribed for treating acute relapses in multiple sclerosis (MS) despite the lack of evidence to support this route of administration. Our double-blind placebo-controlled randomised trial was designed to compare the efficacy of commonly used intravenous and oral steroid regimens in promoting recovery from acute relapses in MS (...) .42 patients with clinically definite relapse in MS received oral, and 38 intravenous, methylprednisolone. Clinical measurements at entry and at 1 week, 4 weeks, 12 weeks, and 24 weeks included Kurtzke's expanded disability status scale (EDSS), Hauser's Ambulatory Index, and an arm-function index. The primary outcome criterion was a difference between the two treatment groups of one or more EDSS grades at 4 weeks.There were no significant differences between the two groups at any stage
1997LancetControlled trial quality: predicted high
Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury To compare the efficacy of methylprednisolone administered for 24 hours with methyprednisolone administered for 48 hours or tirilazad mesylate administered for 48 hours in patients with acute spinal cord injury.Double-blind, randomized clinical (...) trial.Sixteen acute spinal cord injury centers in North America.A total of 499 patients with acute spinal cord injury diagnosed in National Acute Spinal Cord Injury Study (NASCIS) centers within 8 hours of injury.All patients received an intravenous bolus of methylprednisolone (30 mg/kg) before randomization. Patients in the 24-hour regimen group (n=166) received a methylprednisolone infusion of 5.4 mg/kg per hour for 24 hours, those in the 48-hour regimen group (n=167) received a methylprednisolone
High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. The management of episodes of severe pain in patients with sickle cell disease is a difficult clinical problem. We studied 36 children and adolescents with sickle cell disease who had 56 acute episodes of severe pain (44 in 27 patients with sickle cell anemia, 8 in 7 patients with sickle cell-hemoglobin C disease, and 4 in 2 patients with sickle cell-beta (+)-thalassemia (...) ). The patients were randomly assigned in double-blind fashion to receive an intravenous infusion of either saline placebo or high-dose methylprednisolone (15 mg per kilogram of body weight, to a maximum of 1000 mg) on their admission to the hospital and again 24 hours later. All the patients received intravenous morphine sulfate until severe pain abated and were then given acetaminophen with codeine.For all episodes of pain, the duration of inpatient analgesic therapy (intravenous and oral) was significantly